<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01805427</url>
  </required_header>
  <id_info>
    <org_study_id>EXTATIC</org_study_id>
    <secondary_id>EXTATIC</secondary_id>
    <nct_id>NCT01805427</nct_id>
  </id_info>
  <brief_title>Antiretroviral Therapy and Extreme Weight</brief_title>
  <acronym>EXTATIC</acronym>
  <official_title>Extreme Weights and Antiretroviral Therapy Individual Concentrations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hopital Lariboisière</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hopital Lariboisière</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The concentration of the third agent in antiretroviral therapy [Non Nucleoside Reverse&#xD;
      Transcriptase Inhibitor (NNRTI), or boosted Protease inhibitor (PI) ] is different according&#xD;
      to the body weight or body composition and therapeutic monitoring may be necessary in&#xD;
      overweight HIV patients.&#xD;
&#xD;
      The investigators aim at measuring the individual trough concentrations of interest [at&#xD;
      steady state for NNRTI and boosted PI] in overweight and normal weight HIV+ patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our primary endpoint is the individual trough concentrations of interest at steady state for&#xD;
      NNRTI or boosted PI; Principal outcome measure: comparison of the concentrations between&#xD;
      patients &lt;25kg/m2 and patients&lt;25kg/m2&#xD;
&#xD;
      Secondary endpoints:&#xD;
&#xD;
        -  Occurrence of virologic failure&#xD;
&#xD;
        -  Occurrence of clinical/biological adverse events&#xD;
&#xD;
        -  Percentage of patients with concentration within the therapeutic range&#xD;
&#xD;
        -  Body composition Secondary outcome measures: comparison of the occurrence of virologic&#xD;
           failure, occurrence or adverse event, patients with concentration within the therapeutic&#xD;
           range between groups. Correlation between body composition and concentration.&#xD;
&#xD;
      Methodology, study design:&#xD;
&#xD;
      open-labelled monocentric study.&#xD;
&#xD;
      Sample size:&#xD;
&#xD;
      It will be a descriptive experimental study involving 120 overweight subjects, 120 normal&#xD;
      weight subjects&#xD;
&#xD;
      Inclusion criteria :&#xD;
&#xD;
        -  Patients with HIV+&#xD;
&#xD;
        -  Patients aged more than 18 years old.&#xD;
&#xD;
        -  Patient giving its well-informed and free consent.&#xD;
&#xD;
      Study design :&#xD;
&#xD;
      Plasma concentration was performed during the usual clinical follow-up. Study duration: 12&#xD;
      months Duration for a patient: 1 day Investigating center and participating units: one center&#xD;
      enrolling the patients and the lab performing drug dosages.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>comparison of the trough concentrations between patients with Body Mass Index (BMI)&lt;25 kg/m2 and patients with BMI &gt;25 kg/m2</measure>
    <time_frame>the day of enrollment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>comparison of the occurrence of virologic failure within each patient group</measure>
    <time_frame>the day of enrollment</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>occurrence of adverse events in each patient group</measure>
    <time_frame>the day of enrollment</time_frame>
  </other_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">140</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>patients treated with efavirenz</arm_group_label>
    <description>HIV-infected on stable HAART regimen with efavirenz</description>
  </arm_group>
  <arm_group>
    <arm_group_label>patients treated with atazanavir</arm_group_label>
    <description>HIV-infected patients on stable HAART regimen with atazanavir</description>
  </arm_group>
  <arm_group>
    <arm_group_label>patients treated with darunavir</arm_group_label>
    <description>HIV-infected patients on stable HAART regimen with darunavir</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        HIV-infected patients aged 18 years and older, treated with either efavirenz, atazanavir,&#xD;
        or darunavir for at least 4 weeks and under stable treatment regimen&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with HIV+ receiving one of the following third agent their HAART: efavirenz,&#xD;
             atazanavir , or darunavir&#xD;
&#xD;
          -  Patients aged &gt; 18 years old.&#xD;
&#xD;
          -  Patient giving its well-informed and free consent. Patient giving its well-informed&#xD;
             and free consent.&#xD;
&#xD;
        Patients living in France during the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Treatment with rifampin/rifabutin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hopital Lariboisiere</name>
      <address>
        <city>Paris</city>
        <state>Ile-de-France</state>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <study_first_submitted>February 28, 2013</study_first_submitted>
  <study_first_submitted_qc>March 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2013</study_first_posted>
  <last_update_submitted>December 5, 2013</last_update_submitted>
  <last_update_submitted_qc>December 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hopital Lariboisière</investigator_affiliation>
    <investigator_full_name>Stephane Mouly, MD PhD</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <keyword>trough concentration</keyword>
  <keyword>weight</keyword>
  <keyword>HIV</keyword>
  <keyword>virological failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

